Plasma Beta-Thromboglobulin, Fibrinopeptide A and Bβ15–42 Antigen in Relation to Postoperative DVT, Malignancy and Stanozolol Treatment

Summary

Plasma levels of betathromboglobulin (BTG), fibrinopeptide A (FPA) and Bβ15–42 fragment, indices of platelet release, thrombin generation and plasmin activity respectively, were measured in 32 high risk patients during a double blind study of a single dose of the anabolic steroid stanozolol (50 mg IM) in the prevention of DVT after major gastro-intestinal surgery. The prevalence of malignancy and the incidence of DVT (¹²⁵I fibrinogen scan) were similar in the two treatment groups. On the first postoperative day, BTG, FPA and Bβ15–42 levels were increased in most patients. Plasma BTG levels were significantly increased on the first post-operative day in patients who developed a DVT (n = 14) compared to those patients who did not (n = 18). A significant increase in FPA levels was found in the DVT group, 7 days after surgery. On the morning before surgery, plasma Bβ15–42 levels were significantly increased in patients who developed a DVT. In patients undergoing surgery for early malignancy (n = 17), we observed a pre-operative increase in FPA levels when compared to patients without malignancy. At post-operative day 7, Bβ15–42 levels were significantly increased in patients who received stanozolol (n = 15), when compared to the placebo group, suggesting that intramuscular stanozolol increases fibrinolysis in vivo.

Keywords

Fibrinolysis - Post-operative DVT - Malignancy - Stanozolol treatment - Platelet release

• References

• 1 Flute PT, Kakkar VV, Renney J TF, Nicolaides AN. The blood and venous thromboembolism. In: Thrombembolism, Diagnosis and Treatment. Kakkar VV, Jouhar AJ. (Eds) Churchill Livingstone; Edinburgh: 1972. pp 2-12
• 2 Gallus AS, Hirsh J, Gent K. Relevance of preoperative and postoperative blood tests to postoperative leg-vein thrombosis. Lancet 1973; 2: 805-809
• 3 Clayton JK, Anderson JA, McNicol GP. Preoperative prediction of postoperative deep vein thrombosis. Br Med J 1976; 2: 910-912
• 4 Lowe GD O, Osborne DH, McArdle BM, Smith A, Carter DC, Forbes CD, McLaren D, Prentice CR M. Prediction and selective prophylaxis of venous thrombosis in elective gastrointestinal surgery. Lancet 1982; 1: 409-412
• 5 Negus D, Pinto DJ, LeQuesne LP, Brown N, Chapman M. ¹²⁵I labelled fibrinogen in the diagnosis of deep-vein thrombosis and its correlation with phlebography. Br J Surg 1968; 55: 835-839
• 6 Nossel HL. Relative proteolysis of the fibrinogen B-beta chain by thrombin and plasmin as a determinant of thrombosis. Nature 1981; 291: 165-167
• 7 Mansfield AO. Alteration in fibrinolysis associated with surgery and venous thrombosis. Br J Surg 1972; 59: 754-757
• 8 Gordon-Smith IC, Hickman JA, LeQuesne LP. Postoperative fibrinolytic activity and deep vein thrombosis. Br J Surg 1974; 61: 212-218
• 9 Macintyre IM, Weber RG, Crispin JR, Jones DR B, Wood JK, Allan NC, Prescott RJ, Ruckley CV. Plasma fibrinolysis and postoperative deep vein thrombosis. Br J Surg 1976; 63: 694-697
• 10 Browse NL, Gray L, Morland M. Changes in the blood fibrinolytic activity after surgery (the effect of deep vein thrombosis and malignant disease). Br J Surg 1977; 64: 23-27
• 11 Reilly DT, Burden AC, Fossard DP. Fibrinolysis and the prediction of deep vein thrombosis. Br J Surg 1980; 67: 66-68
• 12 Davidson JF, Lockhead M, McDonald GA, McNicol GP. Fibrinolytic enhancement by stanozolol: A double blind trial. Br J Haematol 1972; 22: 5431-5459
• 13 Preston FE, Burakowski BK, Porters N, Malia RG. The fibrinolytic response to stanozolol in normal subjects. Thromb Res 1981; 212: 543-551
• 14 Small M, McArdle BM, Lowe GD O, Forbes CD, Prentice CR M. The effect of intramuscular stanozolol on fibrinoylsis and blood lipids. Thromb Res 1982; 28: 27-36
• 15 Blarney SL, McArdle BM, Burns P, Lowe GD O, Forbes CD. A double-blind trial of intramuscular stanozolol in the prevention of postoperative deep vein thrombosis following elective abdominal surgery. Thromb Haemostas 1984; 51: 71-74
• 16 Small M, Douglas JT, Lowe GD O, Forbes CD. Evidence for increased plasmin activity during stanozolol administration. Lancet 1983; 1: 1114
• 17 Documenta Geigy. Scientific Tables. 7th. ed Macclesfield: Geigy Pharmaceuticals; 1970. p 712
• 18 Douglas JT, Lowe GD O, Forbes CD, Prentice CR M. Plasma fibrinopeptide A and Beta-thromboglobulin in patients with chest pain. Thromb Haemostas 1983; 50: 541-542
• 19 Kudryk B, Robinson D, Netre C, Hessel B, Blomback M, Blomback B. Measurement in human blood of fibrinogen/fibrin fragments containing the Bβl5-42 sequence. Thromb Res 1982; 25: 277-291
• 20 Lane DA, Ireland H, Wolff S, Grant R, Jennings S, Allan-Mersh T. Plasma concentration of fibrinopeptide A, fibrinogen fragment Bβ1-42 and β-thromboglobulin following total hip replacement. Thromb Res 1982; 26: 111-118
• 21 deBoer AC, Han P, Turpie AG G, Butt R, Zielensky A, Genton A. Plasma and urine betathromboglobulin concentrations in patients with deep vein thrombosis. Blood 1981; 58: 693-698
• 22 Torngren S, Noren I, Savidge G. The effect of low dose heparin on fibrinopeptide A, platelets, fibrinogen degradation products and other haemostatic parameters measured in connection with intestinal surgery. Thromb Res 1979; 14: 871-879
• 23 Owen J, Kvam D, Nossel HL, Kaplan KL, Kernoff PB A. Thrombin and plasmin activity and platelet activation in the development of venous thrombosis. Blood 1983; 61: 476-482
• 24 Mellbring G, Dahlgren S, Reiz S, Wiman B. Fibrinolytic activity in plasma and deep vein thrombosis after major abdominal surgery. Thromb Res 1983; 32: 575-584
• 25 Crandon AJ, Peel KR, Anderson JA, Thompson V, McNicol GP. Prophylaxis of postoperative deep vein thrombosis: selective use of low-dose heparin in high-risk patients. Br Med J 1980; 2: 345-347
• 26 Kluft C, Verheijen JH, Cooper P, Chang GT C, Jie AF H, Blarney SL, Lowe GD O, Forbes CD, Preston FE. Postoperative changes in the activity in blood of extrinsic (tissue-type) plasminogen activator and its fast-acting inhibitor. Haemostasis 1984; 14: 41